Dublin, Ireland, October 17, 2013
Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced a scheduled poster presentation at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference taking place on October 19-23 at the Hynes Convention Centre in Boston, USA.
The poster presentation (Abstract #A275) entitled, “Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinases inhibitors.” will be presented by Inflection Biosciences’ research collaborators from the Spanish National Cancer Research Centre (‘CNIO’) on Sunday October 20 from 12:30 - 7:30 pm during Poster Session A; Therapeutic Agents: Small Molecule Kinase Inhibitors 1.
About PIM/PI3 kinase inhibitors The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.
About the Spanish National Cancer Research Centre (CNIO) The CNIO was created in 1998 by the National Health Institute Carlos III, with the essential goal of developing research of excellence and providing innovative technology in the field of cancer. A study published in 2011 (SIR World Report 2011) portrays the centre as the best cancer research entity in the world in terms of Excellence Rate and percentage of high quality publications. Dr Maria Blasco is the Director of the CNIO since June 2011. Since its creation, the CNIO has established collaborations with several national and international companies. Moreover, in the past two years the CNIO has launched two spin-off companies: Life Length, focused on marketing in-house-developed technology for telomere length determination as a novel method of disease risk prediction; and BioncoTech, which develops a new treatment for highly aggressive melanoma. More information available at www.cnio.es
About Inflection Biosciences Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. Based in Ireland and the UK, the Company is creating a pipeline of highly innovative cancer treatments through alliances with leading cancer research organisations. The pipeline includes a novel PIM kinase inhibitor program and a unique multi-targeting kinase inhibitor program in preclinical development. For more information please visit the Company’s website at www.inflectionbio.com
For Further Information Contact:
Darren Cunningham, Chief Executive Officer Inflection Biosciences Ltd email@example.com +353 (0)1 4003615